VP, Program Management

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

• HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
• HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

• HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Vice President, Program Management reports to the Chief Business & Strategy Officer and will lead the cross-functional program management team to maximize the value of Summit’s pipeline drug candidates, with a focus on SMT112 (ivonescimab) and drive execution of the development plans, from multiple clinical trials (including Phase III trials) to BLA / MAA / other regulatory approval filings and commercialization. The Vice President of Program Management is accountable for establishing and maintaining an integrated project plan to cover all aspects of the SMT112 development program.

The Vice President of Program Management should stimulate creative and productive decision making, motivate, determine accountability and urgency, identify opportunities and challenges, and drive robust and informed discussions on risk identification and mitigation strategies. The Vice President of Program Management will lead with influence and have the negotiation and persuasion skills necessary to ensure success of the program and sets goals for the development of Summit’s lead asset, SMT112, and specific program-related goals for the cross-functional team members

Role and Responsibilities:

• Establish and maintain the integrated SMT112 program plan through effective leadership and representation from cross-functional partners, to create and execute a development plan that provides a thorough and clear strategy for maximizing the asset’s chances of development, regulatory, an